Hormonal
Weight loss in obese non-insulin-dependent diabetes mellitus (NIDDM) patients significantly improves glucose homeostasis by reducing basal hepatic glucose output and ameliorating peripheral insulin resistance through enhanced postreceptor glucose transport activity, without requiring increased absolute insulin secretion.
For obese individuals with type 2 diabetes, losing weight is a powerful tool to improve blood sugar control. This improvement comes from two main changes: your liver produces less sugar when you aren't eating, and your muscles become much better at using the insulin you already have. You do not necessarily need to produce more insulin to achieve better blood sugar levels; instead, your body becomes more sensitive to it. This suggests that focusing on sustainable weight loss can significantly reduce the burden of diabetes management.
We conclude that in obese NIDDM, weight loss results in improved glucose homeostasis with 1) reduced basal HGO predominently responsible for the lowering of fasting glucose levels; 2) improved postprandial glucose excursions with marked amelioration of peripheral insulin resistance due to improved postreceptor insulin action, which is at least partly due to enhanced glucose transport system activity; and 3) unchanged absolute insulin levels in the face of markedly reduced glycemia, indicative of enhanced p-cell sensitivity to insulinogenic stimuli.
Why this rating
Small sample size (n=8) but rigorous methodology (euglycemic clamp, isotopic tracers) and clear statistical significance.
Source
Effects of Weight Loss on Mechanisms of Hyperglycemia in Obese Non-Insulin-Dependent Diabetes Mellitus
Robert R. Henry et al. · Diabetes · 1986
DOI 10.2337/diab.35.9.990
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →